THE LEVELS OF ASYMMETRIC DIMETHYLARGININE IN PATIENTS WITH ISOLATED CORONARY ARTERY ECTASIA

Abstract

Keywords

• -

THE LEVELS OF ASYMMETRIC DIMETHYLARGININE IN PATIENTS WITH ISOLATED CORONARY ARTERY ECTASIA

Öz

-

Anahtar Kelimeler

• -

References

1. Swaye PS, Fisher LD, Litwin P, et al. Aneurysmal coronary artery disease. Circulation 1983;67:134–8.
2. H. L. Falsetti, R. J. Carroll, Swope RD, Chen JC. Coronary artery aneurysm. Chest 1976;69:630-6.
3. Giannoglou GD, Antoniadis AP, Chatzizisis YS, Damvopoulou E, Parcharidis GE, Louridas GE. Prevalence of ectasia in human coronary arteries in patients in Northern Greece referred for coronary angiography. The American Journal of Cardiology 2006;98:314–8.
4. Chrissoheris MP, Donohue TJ, Young RSK, Ghantous A. Coronary Artery Aneurysms. Cardiology in Review 2008;16:116–23
5. Yetkin E, Waltenberger J. Novel insights into an old con- troversy: Is coronary artery ectasia a variant of coronary atherosclerosis? Clin Res Cardiol 2007;96:331–9.
6. Papadakis MC, Manginas A, Cotileas P, Demopoulos V, Voudris V, Pavlides G, Foussas SG, Cokkinos DV. Documentation of Slow Coronary Flow by the TIMI Frame Count in Patients With Coronary Ectasia. Am J Card 2001;88:1030-2.
7. Gulec S, Atmaca Y, Kilickap M, Akyürek O, Aras O, Oral D. Angiographic assessment of myocardial perfusion in pa- tients with isolated coronary artery ectasia. Am J Card 2003;91:996-8.
8. Kruger D, Stierle U, Herrmann G, et al. Exercise-induced myocardial ischemia in isolated coronary artery ectasias and aneurysms (“Dilated Coronaropathy”). J Am Coll Cardiol 1999;34:1461–70.

9. Senen K, Yetkin E, Turhan H, et al. Increased thrombolysis in myocardial infartion frame counts in patients with iso- lated coronary artery ectasia. Heart Vessels 2004;19:23-6.
10. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992;20(suppl 12):60-2.
11. Landim MBP, Casella Filho A, Chagas ACP. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics 2009;64(5):471-8.
12. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous ni- tric oxide synthase inhibitor: a novel marker of athero- sclerosis. Circulation 1999;99:1141–6.
13. Boger RH. The emerging role of asymmetric dimethylargi- nine as a novel cardiovascular risk factor. Cardiovasc Res 2003;59:824–33.
14. Cockcroft DW, Gault MH. Prediction of creatinine clear- ance from serum creatinine. Nephron 1976;16:31–41.
15. Hartnell GG, Parnell BM, Pridie RB. Coronary artery ec- tasia—its prevalence and clinical significance in 4993 pa- tients. Br Heart J 1985;54:392–5.
16. Markis JE, Joffe CD, Cohn PF, Feen DJ, Herman MV, Gorlin R. Clinical significance of coronary arterial ectasia. Am J Cardiol 1976; 37: 217-22.
17. Swanton RH, Lea Thomas M, Coltarte DJ, Jenkins BS, Webb-Peploe MM, Williams BT. Coronary artery ectasia, a variant of occlusive coronary arteriosclerosis. Br Heart J 1978;40:393–400.
18. Landmesser U, Drexler H. The clinical significance of en- dothelial dysfunction. Curr Opin Cardiol 2005;20:547–51.
19. Mangieri E, Macchiarelli G, Ciavolella M, et al. Slow coro- nary flow: clinical and histopathological features in pa- tients with otherwise normal epicardial coronary arter- ies. Cathet Cardiovasc Diagn 1996;37:375–81.
20. Cin VG, Pekdemir H, Camsar A, et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 2003;44:907–19
21. Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003;14:155–61.
22. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001;358:2096–7
23. Cooke JP. Asymmetrical dimethylarginine: the Uber mark- er? Circulation 2004;109:1813–8.
24. Sayin T, Doven O, Berkalp B, Akyürek O, Gulec S, Oral D. Exercise induced myocardial ischemia in patients with coronary artery ectasia without obstructive coronary ar- tery disease. Int J Cardiol 2001;78:143–9
25. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angioten- sin II AT1-receptor blockade reduce the levels of asym- metrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002;15:590–3.
26. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship be- tween insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420–6.
27. Mintz GS, Painter JA, Pichard AD, K, et al. Atherosclerosis in angiographically ‘normal’ coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 1995; 5:1479–85.